Clinical Trial Update: Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1% [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study of Adapalene Gel 0.1% was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• Adapalene gel (0.1%) (adapalene)

Snippet

Sponsor: Aurobindo Pharma Ltd | Conditions: Acne Vulgaris | Phase 3 | Status: WITHDRAWN